Lupin Limited has announced a strategic collaboration with Spain-based LABORATORIOS ERN S.A. (ERN) for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed-dose combination therapy delivered through a pressurized metered-dose inhaler (pMDI), in Spain.

The medication is indicated for the treatment of adult patients suffering from asthma and chronic obstructive pulmonary disease (COPD).

The partnership combines Lupin’s expertise in respiratory care and inhalation technology with ERN’s strong commercial presence and established relationships within the Spanish healthcare market. The launch marks another step in Lupin’s strategy to expand access to advanced respiratory treatments across international markets.

Luforbec has already been successfully introduced in key European markets, including the United Kingdom and Germany. The Spain launch is expected to further strengthen Lupin’s respiratory portfolio in the region.

Commenting on the development, Thierry Volle, President – EMEA and Emerging Markets at Lupin, said the collaboration with ERN reinforces the company's commitment to improving access to high-quality respiratory care globally and represents an important milestone in its European growth strategy.

David Solanes, CEO of LABORATORIOS ERN S.A., said the partnership enables ERN to offer a proven respiratory treatment to Spanish patients and healthcare professionals while expanding the company's presence into a new therapeutic segment.